Article info

Download PDFPDF
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Authors

  1. Correspondence to Macarena García Trevijano Cabetas, Hospital Pharmacy Department, La Paz University Hospital, Madrid 28046, Spain; macarena.garciatrevijano{at}salud.madrid.org
View Full Text

Citation

García Trevijano Cabetas M, Escario-Gómez M, González-Del Valle L, et al
Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most?

Publication history

  • Received March 16, 2021
  • Accepted September 28, 2021
  • First published October 7, 2021.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.